Do you believe that the likelihood of generic competition for Angiomax is already priced into the stock valuation, or is it not priced in because it's not a certainty yet?
It’s already priced in, IMO. The stock has been in a downward trend ever since it became clear that MDCO was not going to be able to extend the US patent:
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AI
